Last updated: June 29, 2026
AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc., No. 1:07-cv-00805, is a U.S. patent infringement action tied to Mylan’s FDA-related generic/ANDA entry and AstraZeneca’s asserted Orange Book-listed patent rights for an AstraZeneca product. The docket materials that would identify the specific patents-in-suit, asserted claims, claim construction positions, settlement terms, and final judgment are not present in the provided input, so a complete, accurate litigation summary and analysis cannot be produced under the stated constraints.
What was AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc. No. 1:07-cv-00805 about?
A complete case synopsis requires the docket-record details that define the dispute scope: (i) the drug name and NDA reference product, (ii) the Orange Book patents asserted, (iii) the procedural posture (complaint, answer, motions, Markman, infringement and invalidity phases), (iv) whether the case ended in trial judgment or a Paragraph IV settlement, and (v) any terms tied to launch timing or stipulated injunction/disclaimer.
Case-specific items required for an accurate litigation summary (not provided in the input):
- Patents-in-suit (numbers, assignees, expiration dates)
- Asserted claims and theories (infringement, inequitable conduct, invalidity grounds)
- Parties and counsel identities on the filed briefs
- Procedural milestones (Markman, summary judgment dates, trial dates)
- Final disposition (judgment after trial or settlement dismissal)
- Any consent judgment, stipulated order, or permanent injunction
Which patents were asserted in 1:07-cv-00805 and how strong was the estate?
A strength analysis must be anchored to the specific patent numbers and claim sets litigated. Patent estate assessment typically includes:
- Patent scope (composition vs. method of use vs. formulation vs. manufacturing)
- Claim breadth and dependent claim coverage
- Expiration and remaining term as of filing
- Likely invalidity risks (anticipation, obviousness, lack of written description, indefiniteness, obviousness-type double patenting where applicable)
- Any related PTAB or prior art events affecting claim construction
Without the patents-in-suit and the litigated claim language, any “strength” conclusion would be non-factual.
Did AstraZeneca win at trial or settle? What was the case outcome?
Outcome classification depends on docket disposition:
- Trial verdict and judgment (with infringement and invalidity findings)
- Consent judgment with claim construction adoption
- Settlement under the Hatch-Waxman framework resulting in dismissal
- Narrowed design-around or “carve-out” terms
A litigation summary that reports who prevailed, on what issues, and the final orders requires the final docket entry and the judgment or settlement documentation, which are not included in the input.
How does 1:07-cv-00805 relate to Orange Book listing and Paragraph IV certification?
To analyze Orange Book and Paragraph IV mechanics, the following must be known for this docket:
- Which NDA/Orange Book reference listed patents AstraZeneca asserted
- Which patent certifications Mylan made (Paragraph IV vs. Paragraph III)
- Whether the action was timely under 35 U.S.C. § 271(e)(2) and § 27x litigation filing rules
- Whether the case triggered the 30-month stay and any early resolution
Those facts are not provided, so the Paragraph IV and stay timeline cannot be stated accurately.
What generic entry risks did the AstraZeneca v. Mylan case create?
Generic entry risk assessment needs:
- The injunction or court order scope, if any
- Whether the asserted patents block approval until expiry or until a design-around clears
- Any “non-infringement” findings on specific claims that may map to generic product design
- The presence of additional secondary patents (formulation/process/method-of-use) that can survive an initial settlement
Without docket outcomes and asserted claims, any entry-risk narrative would lack a factual basis.
How would settlement terms typically affect launch timing for Mylan?
Launch-impact analysis requires the actual settlement terms or the court-approved stipulation. Common settlement elements include:
- Date of first commercial marketing (“FCSM”) or “launch” triggers
- Allowed “at-risk” launch windows
- Royalty obligations or lump-sum payments
- Patent carve-outs or covenant not to sue for specified product configurations
- Dismissal scope and any ongoing post-settlement disputes
Those terms are not available in the input.
What is the litigation timeline for 1:07-cv-00805 (filing to disposition)?
A timeline should list:
- Complaint filing date
- Answer and counterclaims
- Markman scheduling and key orders
- Summary judgment dates
- Trial dates (if any)
- Final judgment or settlement dismissal date
No dates or docket entries are provided, so a complete timeline cannot be generated.
How does AstraZeneca v. Mylan compare with other Hatch-Waxman cases involving AstraZeneca and Mylan?
A comparison requires the asserted drug(s), the asserted patent families, and the outcomes across cases. Without the drug identity and patent list from 1:07-cv-00805, no defensible comparison can be made.
Key Takeaways
- No complete litigation summary can be produced from the provided input because the docket-level facts that identify the asserted patents, procedural milestones, claim scope, and outcome are not included.
- Without the patents-in-suit and final disposition, any “who won,” “what patents were invalidated,” “what launch date was permitted,” or “what exclusivity was preserved” would be speculative.
FAQs
-
What patents were at issue in AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc. No. 1:07-cv-00805?
The input does not list the patents-in-suit.
-
Was the case resolved by trial verdict or by settlement?
The input does not include the disposition or final docket entry.
-
Did the case trigger a 30-month Hatch-Waxman stay for Mylan’s ANDA?
The input does not provide the Paragraph IV certification timing or docket entries.
-
What remedies were sought or granted in 1:07-cv-00805 (injunction, damages, declaratory relief)?
The input does not include the relief requested or any court order.
-
How did the outcome affect Mylan’s ability to launch a generic version of AstraZeneca’s product?
The input does not include settlement terms, dismissal scope, or any injunction language.
References (APA)
- AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc., No. 1:07-cv-00805 (case docket and filings not provided in the input).
